stock code: 6564 - twse.com.tw
Post on 16-Oct-2021
4 Views
Preview:
TRANSCRIPT
Stock code: 6564
Enimmune
2
• Found in 2014
• Capital: NTD 600,000,000
• Major shareholder: Adimmune Corporation, Diamond
BioFund, GAINS Investment Corporation, Mega Bank,
Wen Teng Investment
• Business: vaccines & diagnostics developer/distributor
• Product: EV71 vaccine, EV71+CA16 vaccine, JEV
Vaccine, Pneumococcal Vaccine, COVID-19 antigen
rapid test
• Chairman: Chung-Cheng Liu, Ph.D.
• President: Vic Chang, CIA
Millstone
3
2014 2016 2018
2015 2017 2019
Enimmune Corp. was found
EV71 vaccine phase II study was approved by TFDA
Enimmune stock was public offering
CMO inspection by TDFA was completed
EV71 vaccine phase II study was completed.
Enimmune listed on Taiwan emerging stock market
EV71 vaccine phase III study was approved by MO in Vietnam
A+ Industrial Innovative R&D program, MOEA with NTD 24 MM subsidy
EV71 vaccine phase III study was completed
Compliance with the biotech new drug development regulations as the new drug development company
Tuberculin test, PPD test launched in Taiwan
2020
EV71 vaccine NDA filed to TFDA reviewing
Passed GDP inspection
Development for COVID-19 antigen rapid test
Strategy Development
4
drug discovery
development
animal test pre-
clinical
clinical test phase I, II, III
Market IND NDA
Research Development Marketing
Research Institutions, Bio-Tec. Co Enimmune Business Scope
• EV 71 Vaccine Adimmune
• Japanese Encephalitis Vaccine, JEV
• AdimFlu-S (QIS) (privately funded )
• Tuberculin test, PPD
• Tetanus Toxoid, TTA • EV 71 Vaccine
• Pneumococcal Vaccine
• EV71+CA16 vaccine
• Diagnostics
Adimmune
Abcombi
NHRI
• COVID-19 • EV-71 • FLU
top related